Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Su Jie Zhu"'
Publikováno v:
Nongye tushu qingbao xuebao, Vol 35, Iss 10, Pp 34-47 (2023)
[Purpose/Significance] The construction of a reading promotion standard system is the key to achieving the standardization and professional development of reading promotion. The construction of standardized reading promotion is based on reading theor
Externí odkaz:
https://doaj.org/article/ca98ab55c0b346f6889222ed7615b739
Publikováno v:
iMeta, Vol 2, Iss 3, Pp n/a-n/a (2023)
Externí odkaz:
https://doaj.org/article/5648be5dd9094ebe9ca2716488a8ac4a
Autor:
Yue Lu, Zhenzhen Fan, Su‐Jie Zhu, Xiaoxing Huang, Zhongji Zhuang, Yunzhan Li, Zhou Deng, Lei Gao, Xuehui Hong, Ting Zhang, Li Li, Xihuan Sun, Wei Huang, Jingfang Zhang, Yan Liu, Baoding Zhang, Jie Jiang, Fu Gui, Zheng Wang, Qiyuan Li, Siyang Song, Xin Huang, Qiao Wu, Lanfen Chen, Dawang Zhou, Jianming Zhang, Cai‐Hong Yun, Liang Chen, Xianming Deng
Publikováno v:
EMBO Molecular Medicine, Vol 14, Iss 1, Pp 1-13 (2021)
Abstract More than 60% of nonsmall cell lung cancer (NSCLC) patients show a positive response to the first ALK inhibitor, crizotinib, which has been used as the standard treatment for newly diagnosed patients with ALK rearrangement. However, most pat
Externí odkaz:
https://doaj.org/article/c6601c62cfee423f8b9920da0e450eea
Autor:
Shan Li, Tao Zhang, Su-Jie Zhu, Chong Lei, Mengzhen Lai, Lijie Peng, Linjiang Tong, Zilu Pang, Xiaoyun Lu, Jian Ding, Xiaomei Ren, Cai-Hong Yun, Hua Xie, Ke Ding
Publikováno v:
ACS Med Chem Lett
[Image: see text] A series of brigatinib derivatives were designed and synthesized as new potent and selective EGFR(T790M/C797S) inhibitors. One of the most potent and selective compounds 18k strongly suppressed the EGFR(L858R/T790M/C797S) and EGFR(1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bf15482be46b4e9e062a2b8f653c443
https://doi.org/10.1021/acsmedchemlett.1c00555
https://doi.org/10.1021/acsmedchemlett.1c00555
Autor:
Mengzhen Lai, Xianglong Hu, Hua Xie, Su-Jie Zhu, Tao Zhang, Cai-Hong Yun, Qiuju Xun, Tao Huang, Linjiang Tong, Qian Li, Ke Ding, Xiaoyun Lu
Publikováno v:
Chinese Chemical Letters. 31:1281-1287
Extensive structure-activity relationships (SARs) study of JND3229 was conducted to yield a series of new reversible 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidine privileged scaffold as EGFRC797S inhibitors. One of the most potent compound 6i potently s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7296c80f8c9a07894d5e094d0194d950
https://doi.org/10.1016/j.cclet.2019.09.044
https://doi.org/10.1016/j.cclet.2019.09.044
Autor:
Zhang Jingfang, Yunzhan Li, Zhenzhen Fan, Zhuang Zhongji, Li Li, Ting Zhang, Dawang Zhou, Sun Xihuan, Xianming Deng, Liu Yan, Fu Gui, Deng Zhou, Jie Jiang, Su-Jie Zhu, Huang Xiaoxing, Yue Lu, Siyang Song, Jianming Zhang, Xuehui Hong, Zhang Baoding, Qiao Wu, Lanfen Chen, Wei Huang, Xin Huang, Cai-Hong Yun, Qiyuan Li, Liang Chen, Lei Gao, Zheng Wang
Publikováno v:
EMBO Molecular Medicine, Vol 14, Iss 1, Pp n/a-n/a (2022)
EMBO Molecular Medicine
EMBO Molecular Medicine
More than 60% of nonsmall cell lung cancer (NSCLC) patients show a positive response to the first ALK inhibitor, crizotinib, which has been used as the standard treatment for newly diagnosed patients with ALK rearrangement. However, most patients ine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39c99fb8b48695d5a96c8cc1ccc24fb1
https://doaj.org/article/c6601c62cfee423f8b9920da0e450eea
https://doaj.org/article/c6601c62cfee423f8b9920da0e450eea
Autor:
Su-Jie Zhu, Hua Xie, Wei Xu, Ke Ding, Sun Min, Cai-Hong Yun, Xiaoyun Lu, Jiayi Shen, Rong Zhang, Tao Zhang, Linjiang Tong, Jian Ding, Mengzhen Lai, Ruibo Wu
Publikováno v:
Journal of Medicinal Chemistry. 62:7302-7308
Tertiary EGFRC797S mutation induced resistance against osimertinib (1) is an emerging "unmet clinical need" for non-small-cell lung cancer (NSCLC) patients. A series of 5-methylpyrimidopyridone derivatives were designed and synthesized as new selecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91ed1233b1c43c61931039b300127de8
https://doi.org/10.1021/acs.jmedchem.9b00576
https://doi.org/10.1021/acs.jmedchem.9b00576
Autor:
Su-Jie Zhu, Je-Luen Li, Pelin Ayaz, Yibing Shan, Peng Zhao, Casey H Zhang, Xin Huang, Xiao-E Yan, Cai-Hong Yun, Ya-Chuang Wu, Ling Liang, David E. Shaw, Hwan Geun Choi
Publikováno v:
Journal of medicinal chemistry. 63(15)
AZD9291 (Osimertinib) is highly effective in treating EGFR-mutated non-small-cell lung cancers (NSCLCs) with T790M-mediated drug resistance. Despite the remarkable success of AZD9291, its binding pose with EGFR T790M remains unclear. Here, we report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0afa5d6f6cda310b4335c9a9e772cb59
https://pubmed.ncbi.nlm.nih.gov/32672461
https://pubmed.ncbi.nlm.nih.gov/32672461
Autor:
Shan Li, Tao Zhang, Su-Jie Zhu, Chong Lei, Mengzhen Lai, Lijie Peng, Linjiang Tong, Zilu Pang, Xiaoyun Lu, Jian Ding, Xiaomei Ren, Cai-Hong Yun, Hua Xie, Ke Ding
Publikováno v:
ACS Medicinal Chemistry Letters; 2/10/2022, Vol. 13 Issue 2, p196-202, 7p
Autor:
Jiayi, Shen, Tao, Zhang, Su-Jie, Zhu, Min, Sun, Linjiang, Tong, Mengzhen, Lai, Rong, Zhang, Wei, Xu, Ruibo, Wu, Jian, Ding, Cai-Hong, Yun, Hua, Xie, Xiaoyun, Lu, Ke, Ding
Publikováno v:
Journal of medicinal chemistry. 62(15)
Tertiary EGFR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d83b63e6bf6876908ecfd4567eda6202
https://pubmed.ncbi.nlm.nih.gov/31298540
https://pubmed.ncbi.nlm.nih.gov/31298540